← Back to all posts
Drug may repair dna at earliest stages of alzheimer’s – and it’s already passed safety trials
🌟

Drug may repair dna at earliest stages of alzheimer’s – and it’s already passed safety trials

So, there's this exciting new drug called KCL-286 that might just change the game for Alzheimer's treatment! Developed by a team at King’s College London, it not only targets DNA damage but also reduces inflammation, which are both critical early features of the disease. The best part? It has already passed safety trials, meaning we could see it in action much sooner than usual. This approach could offer a broader strategy for tackling Alzheimer's, moving beyond just the usual protein targets.
Read the original article ↗
Share